Trimodality therapy in variant urothelial carcinoma: choose wisely

Vlachostergios, Panagiotis J.; Jakubowski, Christopher; Tagawa, Scott T.

doi:10.21037/tau.2017.03.59

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transurethral resection of bladder tumor (TURBT) remains the primary treatment for NMIBC. In addition to surgical resection, platinum-based chemotherapy and even immunotherapy are crucial for advanced patients, 3 , 4 but the risk of recurrence remains high for patients with distant metastases 5 . The development of resistance to cisplatin has also become the mainobstacle in the treatment of patients with advanced BLCA 6 .…”

Section: Introductionmentioning

confidence: 99%

Hesperetin promotes bladder cancer cells death via the PI3K/AKT pathway by network pharmacology and molecular docking

Lv,

Liu,

Deng

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Patients with bladder cancer (BLCA) still show high recurrence after surgery and chemotherapy. Hesperetin (HE), as a natural compound, has attracted researchers’ attention due to its low toxicity and easy access. However, the inhibitory effect of HE on BLCA remains unknown. The hub genes and enrichment pathways regulated by HE in the treatment of BLCA were predicted by network pharmacology. The molecular docking of HE and hub proteins was visualized. Colony and CCK8 assays were used to test cell proliferation, and BLCA migration was confirmed by transwell and wound healing assays. In addition, the occurrence of apoptosis and ferroptosis was demonstrated by Hoechst staining, transmission electron microscopy (TEM) and ROS (reactive oxygen species) assay. Western Blotting was performed to validate the hub proteins, target functions and pathways. SRC, PIK3R1 and MAPK1 were identified as hub targets for HE in BLCA, involving the PI3k/AKT pathway. Furthermore, HE inhibited the proliferation and migration of BLCA cells. The MMP2/MMP9 proteins were significantly inhibited by HE. The increased expression of Bax and cleaved caspase-3 indicated that HE could promote BLCA cell apoptosis. In addition, Hoechst staining revealed concentrated and illuminated apoptotic nuclei. The activation of ROS and the decline of GPX4 expression suggested that HE might induce ferroptosis as an anti-BLCA process. Shrunk mitochondria and apoptotic bodies were observed in BLCA cells treated with HE, with reduced or absent mitochondrial cristae. We propose for the first time that HE could inhibit the proliferation and migration of BLCA cells and promote apoptosis and ferroptosis. HE may act by targeting proteins such as SRC, PIK3R1 and MAPK1 and the PI3K/AKT pathway.

show abstract

Section: Introductionmentioning

confidence: 99%

Hesperetin promotes bladder cancer cells death via the PI3K/AKT pathway by network pharmacology and molecular docking

Lv,

Liu,

Deng

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In patients with bladder cancer in the muscular infiltrating stage cT2-T4aN0M0, the currently recommended therapy is radical cystectomy preceded by cisplatin-based neoadjuvant chemotherapy. It is possible to perform a partial cystectomy, but these are selected patients with a properly functioning bladder with good capacity and a single localized tumor [6,7].…”

Section: Introductionmentioning

confidence: 99%

“…If this is not possible, atezolizumab, nivolumab (European Medicines Agency (EMA), Food and Drug Administration (FDA) approved), avelumab or durvalumab (FDA approved). Further treatment after platinum and immunotherapy are in clinical trial testing novel antibodydrug conjugates or, in the case of patients with FGFR3 (fibroblast growth factor receptor 3) alterations, FGFR tyrosine kinase inhibitors [6][7][8]. However, due to the lack of alternative therapies, some drugs receive accelerated approval (enfortumab vedotin, sacituzumab govitecan) for some BC patients.…”

Section: Introductionmentioning

confidence: 99%

The Green Anti-Cancer Weapon. The Role of Natural Compounds in Bladder Cancer Treatment

Wigner

Bijak

Saluk‐Bijak

2021

IJMS

View full text Add to dashboard Cite

Bladder cancer (BC) is the second most common genitourinary cancer. In 2018, 550,000 people in the world were diagnosed with BC, and the number of new cases continues to rise. BC is also characterized by high recurrence risk, despite therapies. Although in the last few years, the range of BC therapy has considerably widened, it is associated with severe side effects and the development of drug resistance, which is hampering treatment success. Thus, patients are increasingly choosing products of natural origin as an alternative or complementary therapeutic options. Therefore, in this article, we aim to elucidate, using the available literature, the role of natural substances such as curcumin, sulforaphane, resveratrol, quercetin, 6-gingerol, delphinidin, epigallocatechin-3-gallate and gossypol in the BC treatment. Numerous clinical and preclinical studies point to their role in the modulation of the signaling pathways, such as cell proliferation, cell survival, apoptosis and cell death.

show abstract

Variant Histology: Management Pearls

Regmi

Konety

2021

Bladder Cancer

View full text Add to dashboard Cite

Trimodality therapy in variant urothelial carcinoma: choose wisely

Cited by 3 publications

References 26 publications

Hesperetin promotes bladder cancer cells death via the PI3K/AKT pathway by network pharmacology and molecular docking

Hesperetin promotes bladder cancer cells death via the PI3K/AKT pathway by network pharmacology and molecular docking

The Green Anti-Cancer Weapon. The Role of Natural Compounds in Bladder Cancer Treatment

Variant Histology: Management Pearls

Contact Info

Product

Resources

About